創新 · 品質
誠信 · 堅持
Products Portfolio
ASG's core strength is the development of new dosage forms and new drugs for respiratory inhalation. With the goal of allowing patients to take advantage of every intake and move towards improvements, we aim to change the way of existing drugs delivery from the perspectives of patients and medical staff by using proprietary particles control technology supplemented by customized devices, so that drugs can more effectively enter into the lungs, improve absorption, and enhance efficacy to meet patient needs. The development of new drugs through our patented technological platform currently focuses on four major treatment areas: antibiotics, erectile function, respiratory tract and central nervous system (“CNS”). The development progress of our various products are rapid, and our toxicology studies are near completion within 12 months. Over the next 3 years, we expect to advance into multiple clinical trials around the world.
Alpha Series: Antibiotics and Tuberculosis (“TB”) Treatment
First-line and second-line medications for the treatment of TB are all orally administered antibiotics that inhibit Mycobacterium tuberculosis. The dosage, medication combinations, and the patient's adherence are all key factors that determine whether treatment is successful or not. In order to increase the treatment’s efficacy, reducing the occurrence and development of drug resistance will help to achieve the goal of effectively reducing the number of TB bacteria and ensuring no recurrence after treatment. The principle of the current standard treatment is to combine multiple effective drugs because the maximum (peak) plasma concentration must be reached to have a better and stable efficacy. However, patients need to take so many medications that typically cause discomfort, thereby reducing adherence and the overall therapeutic effect. Through its unique formulation and manufacturing processes, ASG has developed improved new medications for use by patients. The advantages of the DPI dosage are rapid absorption and easy ingestion which creates a better route of administration. It is expected to become a breakthrough in the field of antibiotic treatment and benefit numerous patients.
Beta Series: Erectile Dysfunction Treatment
For the treatment of erectile dysfunction (“ED”), first-line oral drugs are the phosphodiesterase PDE5 inhibitors. The medication is to relax the smooth muscles of the corpus cavernosum and dilate blood vessels to induce erection. It reduces the metabolism of cyclic guanosine monophosphate (“cGMP”) in cells, which can effectively maintain cGMP concentration and prolong erection time. The oral medication needs at least 40 minutes and up to 2 hours to reach its maximum plasma concentration, which means the medication needs to be taken 30 to 60 minutes before sexual activities in order to have better results. However, the active time is too long, and systemic side effects may occur. Improvements through ASG unique formulation design with inhaled drug delivery can accelerate the medication’s absorption rate, coupled with ASG’s customized portable and modern device design that enhances patients’ usage experience and convenience.
Gamma Series: Respiratory Treatment
Excessive secretion of respiratory mucus causes sputum accumulation, which is serious for patients with chronic respiratory diseases. Asthma, chronic bronchitis, cystic fibrosis, and viral or bacterial infections can easily cause respiratory infections. The inflamed trachea will be filled with mucus and coat the foreign bodies that enter the airway to form sputum. When sputum increases and thickens, it blocks the respiratory tract and causes repeated pulmonary inflammation and infection. Especially the elderly or children who are unable to expel sputum by coughing due to poor tracheal ciliary function and a narrow respiratory tract, they must be treated with medication to avoid the accumulation of sputum, which affects breathing and can lead to pneumonia.
Respiratory diseases are one of the major concerns in global health issues, and providing better solutions for respiratory treatment could benefit millions of patients worldwide. The current treatments are all orally ingested medications that can reduce the amount of phlegm and break it down to make it easier to discharge. However, administration through inhalation dosage forms can target and solve the problems more directly, thus making the drug more effective. In addition, it can reduce systemic side effects since the drug acts locally.
Delta Series: CNS Treatment
Currently, CNS analgesics are mainly oral and short-acting. However, it takes a long time, usually about 30 to 40 minutes, for the drug concentration in the blood to reach the effective level. Through our inhalation dosage form and its rapid absorption characteristics, the drug’s intended effect can be quickly achieved to meet clinical needs and reduce systemic side effects.